Influenza vaccination, diagnosis, and treatment in children

Pediatric Emergency Care

Volumn 27, Issue 8, 2011, Pages 760-772

  Chung, Erica Y ^a,b   Chiang, Vincent W ^c,d  

^a RHODE ISLAND HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d South Shore Hospital   (United States)

Author keywords

Influenza; influenza diagnostic test; influenza treatment; influenza vaccination

Indexed keywords

INFLUENZA VACCINE; LIVE VACCINE; OSELTAMIVIR; PLACEBO; ZANAMIVIR;

CHILD; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOFLUORESCENCE; INFLUENZA; INFLUENZA VACCINATION; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY TRACT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; VOMITING;

ANTIVIRAL AGENTS; CHILD; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; OSELTAMIVIR; REAL-TIME POLYMERASE CHAIN REACTION; VACCINATION; ZANAMIVIR;

EID: 80051780259     PISSN: 07495161     EISSN: 15351815     Source Type: Journal    
DOI: 10.1097/PEC.0b013e31822843f2     Document Type: Review

References (120)

1. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood FS, Jain S, Finelli L, et al. Emergence of novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360:2605-2615.
2. Centers for Disease Control and Prevention (CDC). Update: influenza activity-United States, 2009-10 season. MMWR Morb Mortal Wkly Rep. 2010;59(29):901-908.
3. Committee on Infectious Disease. Policy statement: recommendations for prevention and control of influenza in children, 2010-2011. Pediatrics. 2010;126:816-826.
4. Blachere FM, Lindsley WG, Pearce TA, et al. Measurement of airborne influenza virus in a hospital emergency department. Clin Infect Dis. 2009;48:430-440.
5. Bean B, Moore BM, Sterner B, et al. Survival of influenza viruses on environmental surfaces. J Infect Dis. 1982;146:47-51. (Pubitemid 12045334)
6. Boone SA, Gerba CP. The occurrence of influenza Avirus on household and day care center fomites. J Infect. 2005;51:103-109. (Pubitemid 40984343)
7. Wootton SH, Scheifele DW, Mak A, et al. Detection of human influenza virus in the stool of children. Pediatr Infect Dis J. 2006;25:1194-1195. (Pubitemid 44900692)
8. Frank AL, Taber LH, Wells CR, et al. Patterns of shedding of myxoviruses and paramyxoviruses in children. J Infect Dis. 1981;144:433-441. (Pubitemid 12249626)
9. Klimov AI, Rocha E, Hayden FG, et al. Prolonged shedding of amantadine-resistant influenza A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis. 1995;172:1352-1355.
10. American Academy of Pediatrics. Influenza. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009:400-412.
11. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med. 2000;342:232-239. (Pubitemid 30058954)
12. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):1-62.
13. Quach C, Piche-Walker L, Platt R, et al. Risk factors associated with severe influenza infections in childhood: implication for vaccine strategy. Pediatrics. 2003;112:e197-e201.
14. Rojo JC, Ruiz-Contreras J, Fernandez MB, et al. Influenza-related hospitalizations in children younger than three years of age. Pediatr Infect Dis J. 2006;25:596-601. (Pubitemid 43995355)
15. Neuzil KM, Zhu Y, Griffin MR, et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis. 2002;185:147-152. (Pubitemid 34056437)
16. Meury S, Zeller S, Heininger U. Comparison of clinical characteristics of influenza and respiratory syncytial virus infection in hospitalised children and adolescents. Eur J Pediatr. 2004;163:359-363. (Pubitemid 38916369)
17. Wang YH, Huang YC, Chang LY, et al. Clinical characteristics of children with influenza A virus infection requiring hospitalization. J Microbiol Immunol Infect. 2003;36:111-116.
18. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179-186. (Pubitemid 36068705)
19. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292:1333-1340. (Pubitemid 39223224)
20. Maricich SM, Neul JL, Lotze TE, et al. Neurologic complications associated with influenza A in children during the 2003-2004 influenza season in Houston, Texas. Pediatrics. 2004;114:e626-e633. (Pubitemid 41647670)
21. Neurologic complications associated with novel influenza A (H1N1) virus infection in children-Dallas, Texas, May 2009. MMWR Morb Mortal Wkly Rep. 2009;58(28):773-778.
22. Morishima T, Togashi T, Yokota S, et al. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis. 2002;35:512-517.
23. Newland JG, Laurich VM, Rosenquist AW, et al. Neurologic complications in children hospitalized with influenza: characteristics, incidence, and risk factors. J Pediatr. 2007;150:306-310. (Pubitemid 46328959)
24. Steininger C, Popow-Kraupp T, Laferl H, et al. Acute encephalopathy associated with influenza A virus infection. Clin Infect Dis. 2003;36:567-574. (Pubitemid 36259560)
25. Nagao T, Morishima T, Kimura H, et al. Prognostic factors in influenza-associated encephalopathy. Pediatr Infect Dis J. 2008;27:384-389.
26. Mamas MA, Fraser D, Neyses L. Cardiovascular manifestations associated with influenza virus infection. Int J Cardiol. 2008;130:304-309.
27. Guarner J, Paddock CD, Shieh WJ, et al. Histopathologic and immunohistochemical features of fatal influenza virus infection in children during the 2003-2004 season. Clin Infect Dis. 2006;43:132-140.
28. Chen SC, Liu KS, Chang HR, et al. Rhabdomyolysis following pandemic influenza A (H1N1) infection. Neth J Med. 2010;68:317-319.
29. D'Silva D, Hewagama S, Doherty R, et al. Melting muscles: novel H1N1 influenza A associated rhabdomyolysis. Pediatr Infect Dis J. 2009;28:1138-1139.
30. Wu CT, Hsia SH, Huang JL. Influenza BY-associated rhabdomyolysis in Taiwanese children. Acta Paediatr. 2010;99:1701-1744.
31. Abe M, Higuchi T, Okada K, et al. Clinical study of influenza-associated rhabdomyolysis with acute renal failure. Clin Nephrol. 2006;66:166-170. (Pubitemid 44382859)
32. Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med. 2005;353:2559-2567. (Pubitemid 41785893)
33. MacDonald KL, Osterholm MT, Hedberg CW, et al. Toxic shock syndrome: a newly recognized complication of influenza and influenzalike illness. JAMA. 1987;257:1053-1058. (Pubitemid 17031493)
34. Sharkey R, Mulloy E, O'Neill G, et al. Toxic shock syndrome following influenza A infection. Intensive Care Med. 1999;25:335-336. (Pubitemid 29137630)
35. Brundage JF. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis. 2006;6:303-312.
36. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis. 2006;12:894-899. (Pubitemid 43848409)
37. Peltola VT, McCullers JA. Respiratory viruses predisposing to bacterial infections: role of neuraminidase. Pediatr Infect Dis J. 2004;23(suppl 1):S87-S97. (Pubitemid 38168916)
38. Finelli L, Fiore A, Dhara R, et al. Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection. Pediatrics. 2008;122:805-811.
39. Keren R, Zaoutis TE, Bridges CB, et al. Neurological and neuromuscular disease as a risk factor for respiratory failure in children hospitalized with influenza infection. JAMA. 2005;294:2188-2194. (Pubitemid 41571136)
40. Louie JK, Schechter R, Honarmand S, et al. Severe pediatric influenza in California, 2003-2005: implications for immunization recommendations. Pediatrics. 2006;117:e610-e618. (Pubitemid 46071465)
41. Neuzil KM, Wright PF, Mitchel EF Jr, et al. The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr. 2000;137:856-864.
42. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children - diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Disease Society of America. Clin Infect Dis. 2009;48:1003-1032.
43. Neuzil KM, Mellen BG, Wright PF, et al. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med. 2000;342:225-231. (Pubitemid 30058953)
44. O'Brien MA, Uyeki TM, Shay DK, et al. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Ped ia tr i cs. 2004;113:585-593. (Pubitemid 38280802)
45. Schrag SJ, Shay DK, Gershman K, et al. Multistate surveillance for laboratory-confirmed, influenza-associated hospitalizations in children: 2003-2004. Pediatr Infect Dis J. 2006;25:395-400.
46. Neuzil KM, Dupont WD, Wright PF, et al. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J. 2001;20:733-740. (Pubitemid 32758013)
47. France EK, Glanz JM, Xu S, et al. Safety of the trivalent inactivated influenza vaccine among children: a population-based study. Arch Pediatr Adolesc Med. 2004;158:1031-1036. (Pubitemid 39458490)
48. Hambidge SJ, Glanz JM, France EK, et al. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. JAMA. 2006;296:1990-1997. (Pubitemid 44631445)
49. Piedra PA, Yan L, Kotloff K, et al. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics. 2002;110:662-672.
50. Nolan T, Lee MS, Cordova JM, et al. Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities. Vaccine. 2003;21:1224-1231. (Pubitemid 36139953)
51. Vesikari T, Fleming DM, Aristequi JF, et al. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics. 2006;118:2298-2312. (Pubitemid 46397567)
52. Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med. 1998;339:1797-1802. (Pubitemid 29005783)
53. Haber P, DeStefano F, Angulo FJ, et al. Guillain-Barré syndrome following influenza vaccination. JAMA. 2004;292:2478-2481. (Pubitemid 39552672)
54. Juurlink DN, Stukel TA, Kwong J. Guillain-Barré syndrome after influenza vaccination in adults: a population-based study. Arch Intern Med. 2006;166:2217-2221. (Pubitemid 44748768)
55. Vellozzi C, Broder KR, Haber P, et al. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010. Vaccine. 2010;28:7248-7255.
56. James JM, Zeiger RS, Lester MR, et al. Safe administration of influenza vaccine to patients with egg allergy. J Pediatr. 1998;133:624-628. (Pubitemid 28521210)
57. Zeiger R. Current issues with influenza vaccination in egg allergy. J Allergy Clin Immunol. 2002;110:834-840. (Pubitemid 36005868)
58. Chung EY, Huang L, Schneider L. Safety of influenza vaccine administration in egg-allergic patients. Pediatrics. 2010;125:e1024-e1030.
59. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007;356:729-731.
60. Bergen R, Black S, Shinefield H, et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J. 2004;23:138-144. (Pubitemid 38222786)
61. Redding G, Walker RE, Hessel C, et al. Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2002;21:44-48. (Pubitemid 34073958)
62. Peltola V, Reunanen T, Ziegler T, et al. Accuracy of clinical diagnosis of influenza in outpatient children. Clin Infect Dis. 2005;41:1198-1200. (Pubitemid 41429485)
63. Gavin PJ, Thomson RB. Review of rapid diagnostic tests for influenza. Clin Applied Immunol Rev. 2003;4:151-172.
64. Update: infections with a swine-origin influenza A (H1N1) virus-United States and other countries, April 28, 2009. MMWR Morb Mortal Wkly Rep. 2009;58:431-433.
65. Gordon SM. Update on 2009 pandemic influenza A (H1N1) virus. Cleve Clin J Med. 2009;76:577-582.
66. Uyeki TM, Prasad PP, Vukotich C, et al. Low sensitivity of rapid diagnostic test for influenza. Clin Infect Dis. 2009;48:e89-e92.
67. Hurt AC, Alexander R, Hibbert J, et al. Performance of six influenza rapid tests in detecting human influenza in clinical specimens. J Clin Virol. 2007;39:132-135. (Pubitemid 46777422)
68. Grijalva CG, Poehling KA, Edwards KM, et al. Accuracy and interpretation of rapid influenza tests in children. Pediatrics. 2007;119:e6-e11. (Pubitemid 46397799)
69. Centers for Disease Control and Prevention (CDC). Evaluation of rapid influenza diagnostic tests for detection of novel influenza A (H1N1) virus-United States, 2009. MMWR Morb Mortal Wkly Rep. 2009;58:826-829.
70. Faix DJ, Sherman SS, Waterman SH. Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;361:728-729.
71. Chan KH, Lai ST, Poon LL, et al. Analytical sensitivity of rapid influenza antigen detection tests for swine-origin influenza virus (H1N1). J Clin Virol. 2009;45:205.
72. Likitnukul S, Boonsiri K, Tangsuksant Y. Evaluation of sensitivity and specificity of rapid influenza diagnostic tests for novel swine-origin influenza A (H1N1) virus. Pediatr Infect Dis J. 2009;28:1038-1039.
73. Drexler JF, Helmer A, Kirberg H, et al. Poor clinical sensitivity of rapid antigen test for influenza A pandemic (H1N1) 2009 virus. Emerg Infect Dis. 2009;15:1662-1664.
74. Ginocchio CC, Zhang F, Manji R, et al. Evaluation of multiple test methods for the detection of the novel 2009 influenza A (H1N1) during the New York City outbreak. J Clin Virol. 2009;45:191-195.
75. Vasoo S, Stevens J, Singh K. Rapid antigen tests for diagnosis of pandemic (swine) influenza A/H1N1. Clin Infect Dis. 2009;49:1090-1093.
76. Lee HM, Park HK, Hwang H, et al. Diagnostic value of the rapid influenza antigen test for novel influenza A (H1N1). Scand J Infect Dis. 2011;43:43-46.
77. Taylor J, McPhie K, Druce J, et al. Evaluation of twenty rapid antigen tests for the detection of human influenza A H5N1, H3N2, H1N1, and B Viruses. J Med Virol. 2009;81:1918-1922.
78. Uyeki TM. Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza. Pediatr Infect Dis J. 2003;22:164-177. (Pubitemid 36228135)
79. Rahman M, Kieke BA, Vandermause MF, et al. Performance of Directigen flu A+B enzyme immunoassay and direct fluorescent assay for detection of influenza infection during the 2004-2005 season. Diagn Microbiol Infect Dis. 2007;58:413-418. (Pubitemid 47198409)
80. Sato M, Hosoya M, Kato K, et al. Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. Pediatr Infect Dis J. 2005;24:931-932. (Pubitemid 41475935)
81. Frayha H, Castriciano S, Mahony J, et al. Nasopharyngeal swabs and nasopharyngeal aspirates equally effective for the diagnosis of viral respiratory disease in hospitalized children. J Clin Microbiol. 1989;27:1387-1389. (Pubitemid 19136441)
82. Heikkinen T, Marttila J, Salmi AA, et al. Nasal swab versus nasopharyngeal aspirate for isolation of respiratory viruses. J Clin Microbiol. 2002;40:4337-4339. (Pubitemid 35285840)
83. Lambert SB, Whiley DM, O'Neill NT, et al. Comparing nose-throat swabs and nasopharyngeal aspirates collected from children with symptoms for respiratory virus identification using real-time polymerase chain reaction. Pediatrics. 2008;122:e615-e620.
84. Sung RY, Chan PK, Choi KC, et al. Comparative study of nasopharyngeal aspirate and nasal swab specimens for diagnosis of acute viral respiratory infection. J Clin Microbiol. 2008;46:3073-3076.
85. Noyola DE, Demmler GJ. Effect of rapid diagnosis on management of influenza A infections. Pediatr Infect Dis J. 2000;19:303-307. (Pubitemid 30213068)
86. Sharma V, Dowd D, Slaughter AJ, et al. Effect of rapid diagnosis of influenza virus type A on the emergency department management of febrile infants and toddlers. Arch Pediatr Adolesc Med. 2002;156:41-43. (Pubitemid 34049109)
87. Poehling KA, Zhu Y, Tang Y, et al. Accuracy and impact of a point-of-care rapid influenza test in young children with respiratory illnesses. Arch Pediatr Adolesc Med. 2006;160:713-718.
88. Abanses JC, Dowd MD, Simon SD, et al. Impact of rapid influenza testing at triage on management of febrile infants and young children. Pediatr Emerg Care. 2006;22:145-149.
89. Bonner AB, Monroe KW, Talley LI, et al. Impact of the rapid diagnosis of influenza on physician decision-making and patient management in the pediatric emergency department: results of a randomized, prospective, controlled trial. Pediatrics. 2003;112:363-367. (Pubitemid 36951400)
90. Hall CB, Edwards MS, Mallory GB, et al. Clinical features and diagnosis of influenza in children. UpToDate Online 18.2. January 26, 2010. Available at: www.uptodate.com. Accessed October 13, 2010.
91. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005;353:1363-1373. (Pubitemid 41362704)
92. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001;20:127-133. (Pubitemid 32151932)
93. Matheson NJ, Harnden AR, Perera R, et al. Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev. 2007; (1): CD002744.
94. Hedrick JA, Barzilai A, Behre U, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J. 2000;19:410-417. (Pubitemid 30307990)
95. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet. 1998;352:1877-1881.
96. Makela MJ, Pauksens K, Rostila T, et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect. 2000;40:42-48. (Pubitemid 30157772)
97. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis. 1999;180:254-261. (Pubitemid 30256303)
98. Sugaya N, Tamura D, Yamazaki M, et al. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clin Infect Dis. 2008;47:339-345. (Pubitemid 352009352)
99. Peters PH, Moscona A, Schulman KL, et al. Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005. Medscape J Med. 2008;10:131.
100. Barr CE, Schulman K, Iacuzio D, et al. Effect of oseltamivir on the risk of pneumonia and use of health care services in children with clinically diagnosed influenza. Curr Med Res Opin. 2007;23:523-531. (Pubitemid 46456900)
101. Puhakka T, Lehti H, Vainionpaa R, et al. Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza. Scand J Infect Dis. 2003;35:52-58. (Pubitemid 36336368)
102. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet. 2000;355:1845-1850. (Pubitemid 30311875)
103. Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis. 2004;189:440-449. (Pubitemid 38210580)
104. Dutkowski R, Thakrar B, Froehlich E, et al. Safety and pharmacology of oseltamivir in clinical use. Drug Saf. 2003;26:787-801. (Pubitemid 37056109)
105. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. GG167 Influenza Study Group. N Engl J Med. 1997;337:874-880. (Pubitemid 27408569)
106. Williamson JC, Pegram PS. Respiratory distress associated with zanamivir. N Engl J Med. 2000;342:661-662.
107. GSK. Zanamivir [package insert]. Philadelphia, PA: GSK; 2008. Available at: http://us.gsk.com/products/assets/us-relenza.pdf. Accessed October 11, 2010.
108. Murphy KR, Elvindson A, Pauksens K, et al. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease: a double-blind, randomised, placebo-controlled, multicentre study. Clin Drug Investig. 2000;20:337-349.
109. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001;285:748-754. (Pubitemid 32167233)
110. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl J Med. 2000;343:1282-1289.
111. Monto AS, Pichichero ME, Blanckenberg SJ, et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis. 2002;186:1582-1588. (Pubitemid 35379634)
112. Centers for Disease Control and Prevention. Update: influenza activity-United States, September 30, 2007-February 9, 2008. MMWR Morb Mortal Wkly Rep. 2008;57:179-183.
113. Hauge SH, Dudman SG, Borgen K, et al. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis. 2009;15:155-162.
114. Lackenby A, Hungnes O, Dudman SG, et al. Emergence of resistance to oseltamivir among influenza A (H1N1) viruses in Europe. Euro Surveill. 2008;13:8026.
115. Besselaar TG, Dhamari N, Buys A, et al. Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa. Emerg Infect Dis. 2008;14:1809-1810.
116. Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother. 2008;52:3284-3292.
117. Centers for Disease Control and Prevention. CDC issues interim recommendations for the use of influenza antiviral medications in the setting of oseltamivir resistance among circulating influenza A (H1N1) viruses, 2008-09 influenza season. 2008. Available at: http://www2a.cdc.gov/HAN/ArchiveSys/ ViewMsgV.asp?AlertNump00279. Accessed October 5, 2010.
118. World Health Organization (WHO). Influenza A (H1N1) Virus Resistance to OseltamivirV2008/2009 Influenza Season, Northern Hemisphere. Geneva, Switzerland: WHO; 2009. Available at: http://www.who.int/csr/disease/influenza/ h1n1-table/en/index.html. Accessed October 5, 2010.
119. Update: influenza activity-United States, September 28, 2008-April 4, 2009, and composition of the 2009-10 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2009;58:369-374.
120. Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep. 2009;58:433-435.